European Pharmaceutical Review

JANUARY 19, 2024

An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable, and endocrine therapy in patients with hormone receptor (HR)-positive breast cancer, if suitable.

Chemotherapy 98

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 98

pharmaphorum

JULY 14, 2022

. “We’ll continue to demand more for people affected by breast cancer, working with the Government, NHS England, NICE and pharmaceutical companies to ensure new, clinically effective treatments reach patients as quickly as possible, at a fair price for the NHS,” she added.

Chemotherapy 104

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 104

Hospital Pharmacy Europe

SEPTEMBER 11, 2024

New responsibilities, new arenas The potential for in-hospital manufacturing is further developing due to the new responsibilities assigned to hospital pharmacy staff, such as centralised preparation of chemotherapies and drugs for clinical trials, extemporaneous production of radiopharmaceuticals and cellular therapies, to name but a few.

Hospitals 52

Hospitals Community Pharmacies Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 16, 2023

Designated as BG01-2202, this latest trial will be an open-label, randomised, controlled clinical study of UTD1 versus chemotherapy drug docetaxel. A Phase III study to evaluate UTD1 versus docetaxel in patients that have failed chemotherapy with a platinum-containing regimen is also currently underway in China. ORR, 81.0%

FDA 52

FDA Chemotherapy Labelling Pharmaceutical Companies 52